

Enforcement Actions

Corporate Integrity Agreement

On April 23, 2014, *with no admissions of liability on its part*, Amedisys, Inc. entered into a settlement agreement with the U.S. Department of Justice relating to certain of its clinical and business operations. Concurrently with Amedisys, Inc.'s entry into this agreement, it entered into a corporate integrity agreement ("CIA") with the Office of Inspector General-HHS ("OIG"). The CIA formalizes various aspects of Amedisys, Inc.'s already existing ethics and compliance programs and contains other requirements designed to help ensure Amedisys, Inc.'s ongoing compliance with federal health care program requirements. Among other things, the CIA requires Amedisys, Inc. to maintain its existing compliance program and management compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue screening new and current employees against certain lists to ensure they are not ineligible to participate in federal health care programs; engage an independent review organization to perform certain auditing and reviews and prepare certain reports regarding its compliance with Federal health care programs, its billing submissions to federal health care programs and its compliance and risk mitigation programs; and provide certain reports and management certifications to Office of Inspector General-HHS. Among other things, the CIA requires that Amedisys, Inc. report substantial overpayments that it discovers it has received from federal health care programs, as well as probable violations of federal health care laws. Upon breach of the CIA, Amedisys, Inc. could become liable for payment of certain stipulated penalties, or could be excluded from participation in federal health care programs. The corporate integrity agreement has a term of five years.

Subpoena Duces Tecum Issued by the U.S. Department of Justice

On May 21, 2015, Amedisys, Inc. received a Subpoena Duces Tecum ("Subpoena") issued by the U.S. Department of Justice. The Subpoena requests the delivery of information regarding 53 identified hospice patients to the United States Attorney's Office for the District of Massachusetts. It also requests the delivery of documents relating to Amedisys, Inc.'s hospice clinical and business operations and related compliance activities. The Subpoena generally covers the period from January 1, 2011, through the present. Amedisys, Inc. is fully cooperating with the U.S. Department of Justice with respect to this investigation. No assurance can be given as to the timing or outcome of this investigation.

Civil Investigative Demand Issued by the U.S. Department of Justice

On November 3, 2015, Amedisys, Inc. received a civil investigative demand ("CID") issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requests the delivery of information to the United States Attorney's Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covers the period from January 1, 2009 through August 31, 2015. Amedisys, Inc. is fully cooperating with the U.S. Department of Justice with respect to this investigation. No assurance can be given as to the timing or outcome of this investigation.